biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline

Download this as a PDF BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 - 400 Burrard Street, Vancouver, BC, on January 23, [...]

By | Monday, January 23, 2017|2017 Press Releases, Corporate Press Releases|

biOasis Announces Adoption of Restricted Share Unit Plan

Download this as a PDF December 22nd, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) announces that subject to approval by the TSX Venture Exchange ("TSXV") and ratification by the Company's shareholders at the 2016 Annual and Special General Meeting of shareholders (the "AGM"), the Company adopted a restricted share unit plan (the [...]

By | Friday, December 23, 2016|2016 Press Releases, Corporate Press Releases, Uncategorized|

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research’s December Journal

Download this as a PDF November 6th, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it’s team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. [...]

By | Monday, November 7, 2016|2016 Press Releases, Corporate Press Releases|

biOasis Engages Rising Tide Equity to Increase Global Awareness

Download this as a PDF October 23rd, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media [...]

By | Tuesday, October 25, 2016|2016 Press Releases, Corporate Press Releases|

biOasis Enters Into a License Agreement With Vaccinex Inc

Download this as a PDF September 20th, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex [...]

By | Tuesday, September 27, 2016|2016 Press Releases, Corporate Press Releases|

biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model

Download this as a PDF August 29, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ [...]

By | Monday, August 29, 2016|2016 Press Releases, Corporate Press Releases|

biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier.

Download this as a PDF July 10, 2016, VANCOUVER BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of [...]

By | Sunday, July 10, 2016|2016 Press Releases, Corporate Press Releases|

CEO Blog: CEO REPORT: Rob Hutchison, CEO

Our biOasis team recently attended the BIO International Convention in San Francisco, California (June 6 -­‐ 9). The conference is one of the largest of its kind in the world, attracting over 15,000 biotechnology and pharmaceutical industry leaders who come together for a week of intensive networking to discover new opportunities and promising partnerships. Our [...]

By | Monday, June 27, 2016|CEO Blog|

biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016

Download this as a PDF May 17, 2016, VANCOUVER BC biOasis to showcase their Transcend technology for the transport of drugs across the blood-brain barrier (BBB) BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it will be [...]

By | Tuesday, May 17, 2016|2016 Press Releases, Corporate Press Releases|